Nuvasive Stock News

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE , ", Sorrento", )) today announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President. Mr. Asghar died of apparent natural causes on January 6, 2022. "Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Najjam''s family and friends," said Dr. Henry Ji, Sorrento''s Chairman and CEO. "We appreciate and thank Najjam for his tremendous contributions to Sorrento and the San Diego life sciences community." Mr. Asghar joined Sorrento in June 2019 from NuVasive, Inc., where he served as VP, Accounting and Finance since October 2015. At Sorrento, Mr. Asghar served as Chief Financial Officer, leading the functions of Finance, Accounting and Tax. Mr. Asghar started his career with PricewaterhouseCoopers, where he served various S&P 100 and S&P 500 clients in North America and Asia in the audit and assurance practice.

NuVasive Inc. (NASDAQ:NUVA) concluded the trading at $52.35 on Thursday, December 23 with a rise of 1.02% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $51.82 and 5Y monthly beta was reading 1.30 with its price kept floating in the range NuVasive Inc. (NUVA) Recovers 15.18% From Low: Are We There Yet? Read More »

NuVasive (NASDAQ:NUVA) had its target price reduced by equities research analysts at Truist Securities from $75.00 to $60.00 in a report issued on Tuesday, Price Targets.com reports. The brokerage presently has a buy rating on the medical device companys stock. Truist Securities price objective would suggest a potential upside of 15.79% from the stocks previous []

WCM Investment Management LLC grew its holdings in shares of NuVasive, Inc. (NASDAQ:NUVA) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 207,738 shares of the medical device company’s stock after purchasing an additional 1,218 shares during the quarter. WCM Investment Management […]

NuVasive (NASDAQ:NUVA) and Sigyn Therapeutics (NASDAQ:SIGY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Valuation and Earnings This table compares NuVasive and Sigyn Therapeutics top-line revenue, earnings per share (EPS) and []

Equities analysts expect NuVasive, Inc. (NASDAQ:NUVA) to report earnings of $0.48 per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for NuVasives earnings. The lowest EPS estimate is $0.43 and the highest is $0.52. NuVasive posted earnings per share of $0.59 during the same quarter last year, which []

Equities research analysts expect NuVasive, Inc. (NASDAQ:NUVA) to announce sales of $298.91 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for NuVasives earnings. The lowest sales estimate is $295.58 million and the highest is $303.16 million. NuVasive posted sales of $291.81 million during the same quarter last year, which []

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: GMED) market share gains in 2022, according to BofA Securities. The Globus Medical Analyst: Craig Bijou upgraded the rating fo

Oregon Public Employees Retirement Fund lowered its stake in shares of NuVasive, Inc. (NASDAQ:NUVA) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 17,263 shares of the medical device companys stock after selling 238 shares during the quarter. Oregon Public Employees Retirement Funds []

NuVasive, Inc. (NASDAQ:NUVA) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 4,970,000 shares, a growth of 25.5% from the October 31st total of 3,960,000 shares. Currently, 9.7% of the shares of the company are sold short. Based on an []

NuVasive, Inc. (NASDAQ:NUVA) has earned an average rating of Hold from the sixteen analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among []

Equities research analysts expect that NuVasive, Inc. (NASDAQ:NUVA) will report $298.91 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for NuVasives earnings, with the highest sales estimate coming in at $303.16 million and the lowest estimate coming in at $295.58 million. NuVasive posted sales of []

Global Orthopaedic Braces and Supports Market Synopsis: Orthopaedic Braces and Supports Market survey report analyses the changing trends in the industry. This Market report is a comprehensive background analysis of the Healthcare industry which includes an assessment of the parental Market.